bioAffinity Technologies ... (BIAF)
| Bid | 0.48 |
| Market Cap | 9.06M |
| Revenue (ttm) | 9.36M |
| Net Income (ttm) | -9.04M |
| EPS (ttm) | -0.75 |
| PE Ratio (ttm) | -0.66 |
| Forward PE | -1.2 |
| Analyst | Buy |
| Ask | 0.51 |
| Volume | 302,930 |
| Avg. Volume (20D) | 9,680,934 |
| Open | 0.52 |
| Previous Close | 0.54 |
| Day's Range | 0.47 - 0.53 |
| 52-Week Range | 0.24 - 3.16 |
| Beta | 3.47 |
About BIAF
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas....
Analyst Forecast
According to 1 analyst ratings, the average rating for BIAF stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 1108.95% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · businesswire.com
Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer RecurrenceSAN ANTONIO--(BUSINESS WIRE)-- #BIAF--In another case study, CyPath® Lung helped physicians identify and treat a recurrence of breast cancer in a high-risk patient.
1 month ago · businesswire.com
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 MillionSAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity has entered into warrant exercise agreements to exercise certain outstanding warrants for gross cash proceeds of $1.4 million.
